LIGAND PHARMACEUTICALS INCORPORATED Deferred Foreign Income Tax Expense (Benefit)
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported Deferred Foreign Income Tax Expense (Benefit) of -$6.22 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-27
- LIGAND PHARMACEUTICALS INCORPORATED deferred foreign income tax expense (benefit) for fiscal 2025 was -$6.22M, a 429.21% decline from fiscal 2024.
- LIGAND PHARMACEUTICALS INCORPORATED deferred foreign income tax expense (benefit) for fiscal 2024 was $1.89M.
- LIGAND PHARMACEUTICALS INCORPORATED deferred foreign income tax expense (benefit) for fiscal 2023 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED deferred foreign income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$6.22M 10-K · filed 2026-02-27 |
| 2024-12-31 | $1.89M 10-K · filed 2026-02-27 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-27 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |
| 2018-12-31 | $0.00 10-K · filed 2019-02-28 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-28 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-28 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-01 |